
Carolina Saldana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/145122/publications.pdf Version: 2024-02-01



CAROLINA SALDANA

#	Article	IF	CITATIONS
1	First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 2016, 107, 44-53.	4.4	25
2	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. European Journal of Cancer, 2020, 136, 76-83.	2.8	19
3	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel GroupÂstudy. European Journal of Cancer, 2017, 80, 55-62.	2.8	18
4	Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma. European Journal of Cancer, 2021, 151, 106-114.	2.8	18
5	Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data. Cancer Treatment Reviews, 2021, 97, 102191.	7.7	17
6	CIMUC: Chemotherapy following Immune checkpoints inhibitors in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) Journal of Clinical Oncology, 2022, 40, 492-492.	1.6	13
7	Everolimus and sunitinib as first- and second-line treatments of patients with metastatic papillary renal cell carcinoma (pRCC): A retrospective study of the GETUG (Groupe Français d'Etude des) Tj ETQq1 1	0.784314	rg & T /Overl
8	Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, 2021, 19, 554-562.	1.9	6
9	Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study Journal of Clinical Oncology, 2019, 37, 582-582.	1.6	4
10	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). European Journal of Cancer, 2021, 158, 1-11.	2.8	4
11	Acute tubular necrosis after selective FGFR tyrosine kinase inhibitor therapy. European Journal of Cancer, 2020, 139, 177-180.	2.8	1
12	ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC) Journal of Clinical Oncology, 2021, 39, 5046-5046.	1.6	1
13	Metastatic chromophobe renal cell carcinoma treated with target therapies: A Renal Cross Chanel Group (RCCG) study Journal of Clinical Oncology, 2015, 33, 4561-4561.	1.6	1
14	Blood alcohol level in patients treated with gemcitabine and taxanes Journal of Clinical Oncology, 2015, 33, e17664-e17664.	1.6	0
15	First line antiangiogenics for advanced renal cell carcinoma: A systematic review and network meta-analysis comparing efficacy and toxicities Journal of Clinical Oncology, 2015, 33, e15586-e15586.	1.6	0
16	Clinical criteria predicting an overall survival benefit to platinum rechallenge (PR) in metastatic urothelial cancer (mUC) Journal of Clinical Oncology, 2020, 38, 490-490.	1.6	0